Gefimet 250 Tablet
Marketer
Axiommax Oncology Pvt Ltd
Salt Composition
Gefitinib (250mg)
Overview Gefimet 250 Tablet
Aflibercept 250mg tablets are indicated for treating metastatic non-small cell lung cancer. This medication is prescribed for patients with abnormal epidermal growth factor receptor (EGFR) genes whose cancer has metastasized and who are treatment-naive. Dosage should strictly adhere to your physician's instructions, continuing therapy as directed. Treatment duration is individualized based on response and needs. Regular liver function monitoring may be recommended. Common adverse effects include nausea, dry skin, appetite loss, and diarrhea. Increased fluid intake may mitigate side effects. Report any concerning or worsening side effects to your doctor immediately. Seek immediate medical attention if you experience oral ulceration, visual disturbances, or respiratory difficulties. Effective contraception is mandatory during treatment and for one month post-treatment for women. Always inform your physician of all other concurrent medications.
Uses of Gefimet 250 Tablet
Lung cancer (excluding small cell type)
Major Benefits of Gefimet 250 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. The tablet should be swallowed whole; avoid chewing, crushing, or breaking it. Gefimet 250 Tablets can be taken with or without food, however, consistency in timing is recommended.
Common Side effects of Gefimet 250 Tablet:
- Diarrhea
- Dry skin
- Loss of appetite
- Nausea
- Rash
- Vomiting
- Weakness
- Weight loss
- Eating disorder
- Allergic reaction
How to use Gefimet 250 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Gefimet 250 Tablet whole; do not crush, chew, or divide it. This medication can be taken with or without food, however, consistency in timing is recommended.
How Gefimet 250 Tablet works:
Gefimet 250 Tablets are an anticancer drug that inhibits the activity of a faulty protein responsible for cancer cell proliferation, thus impeding or retarding tumor growth.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol alongside Gefimet 250 Tablets poses a safety risk.
PregnancyCONSULT YOUR DOCTOR
Using Gefimet 250 Tablets during pregnancy poses a confirmed risk to the fetus. Its use should only be considered in exceptional, life-threatening circumstances where the potential benefits clearly outweigh the known hazards, as determined by a physician. Always seek medical advice before taking this medication.
Breast feedingCONSULT YOUR DOCTOR
Lactation and the use of Gefimet 250 Tablets are likely incompatible. Preliminary evidence in humans indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Driving ability may be impaired by the use of Gefimet 250 Tablets, which may produce adverse effects.
KidneyCAUTION
Patients with severe kidney impairment should exercise caution when using Gefimet 250 Tablets. Dosage modification may be necessary; physician consultation is advised.
LiverSAFE IF PRESCRIBED
Use of Gefimet 250 Tablet in patients with liver disease appears to present minimal risk. Preliminary findings indicate dose modification may be unnecessary, however, physician consultation is advised.
What if you forget to take Gefimet 250 Tablet :
Omit any missed Gefimet 250 Tablet dose and resume your regular medication regimen. Avoid taking a double dose.
Facts to Know About Gefimet 250 Tablet
| Label | Value |
|---|---|
| Type of Compound | Quinazoline derivatives containing an amine functional group. |
| Potential for Dependence | None. |
| Type of Medication | Cancer therapeutics |
3,018 People bought this recently